MK1026-010

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)

Enquire

Trial overview

Disease

Haematology

Topic

MK1026-011

Sponsor

MSD

Description

Study details

For detailed information on this trial, please click here

Trial status

Open April 24

Location

Cambridge

Priniciple Investigator

Professor George Follows

MA, BM BCh (Oxon), PhD, FRCP, FRCPath

Consultant haematologist